Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Riocare India Pvt Ltd

    RioCare has an annual capacity of 400 MT and currently supplies its products to companies in the Asian, South East Asian, Middle Eastern and American markets.

  • No Image
    Roche Products India Pvt Ltd

    Roche Products (India) Private Limited (formerly known as ?Roche Scientific Company (India) Pvt. Ltd.?) was incorporated in 1994 as a wholly owned subsidiary of Roche Group. In

  • No Image
    Roopa Industries Ltd

    Roopa Industries Ltd. is one of the growing pharmaceutical companies in India which has been steadily diversifying its product portfolio. The company has a manpower of 150+ well

  • No Image
    RPG Life Sciences Ltd

    RPG Life Sciences, a part of the Rs. 17,000 crore RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the Branded For

  • No Image
    Rusan Pharma Ltd

    Rusan Pharma started operations in 1994 by manufacturing commercial scale Buprenorphine Hydrochloride. The Indian Process Patent for Buprenorphine Hydrochloride rests with their